Skip to main content

HIV Surveillance By Testing Saliva

Saliva specimens were tested for HIV antibody (anti-HIV) by an immunoglobulin G (IgG) antibody capture radioimmunoassay (GACRIA) and three sensitive commercial assays. In tests on 460 seronegative subjects and 196 seropositive subjects GACRIA was 99.8% specific and 100% sensitive. The Wellcome HIV monoclonal and Abbott recombinant DNA enzyme-linked immunosorbent assays (ELISAs) were also highly specific (99.8%, 100%) but they were less sensitive (90.9%, 82.0%). The Fujirebio particle agglutination assay was sensitive (97.8%) but its specificity was poor (84.1%). In testing saliva specimens from populations with an anti-HIV prevalence greater than 0.5%, sampling by GACRIA alone could provide a good estimate of the true prevalence. For true prevalences less than 0.5% good estimates could only be obtained if positive GACRIA reactions were confirmed by another independent salivary assay. Salivary testing for anti HIV is a convenient and potentially an accurate epidemiological tool.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nicole Makosso.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Makosso, N. HIV Surveillance By Testing Saliva. Retrovirology 2, P62 (2005). https://doi.org/10.1186/1742-4690-2-S1-P62

Download citation

Keywords

  • True Prevalence
  • Antibody Capture
  • Commercial Assay
  • Agglutination Assay
  • Particle Agglutination